Head and neck osteosarcomas: Analysis of treatment trends and survival outcomes in the United States (2004-2016).
Head Neck
; 43(11): 3294-3305, 2021 11.
Article
em En
| MEDLINE
| ID: mdl-34272901
ABSTRACT
BACKGROUND:
Head and neck osteosarcoma (HNOS) is a rare primary bone tumor with limited data to guide treatment approaches.METHODS:
The NCDB was used to identify patients diagnosed with HNOS. Kaplan-Meier and Cox multivariate regression were used to examine the impact of each treatment on overall survival (OS).RESULTS:
We identified 821 patients diagnosed with HNOS. Utilization of neoadjuvant chemotherapy + surgery increased from zero cases in 2004 to 24% of cases in 2016. Among surgically treated patients, 5-year OS was 55.8% (CI 51.7-60.1%). No difference was seen in OS between each treatment cohort on multivariate analysis. However, neoadjuvant chemotherapy + surgery + adjuvant chemotherapy had improved 18-month survival compared to surgery alone (95.8% vs. 78.5%, p = 0.031).CONCLUSIONS:
Our study demonstrated no survival benefit in perioperative chemotherapy or radiation therapy; however, short-term survival improvement in patients receiving both neoadjuvant and adjuvant chemotherapy displays promise and requires further investigation.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Neoplasias Ósseas
/
Osteossarcoma
Idioma:
En
Ano de publicação:
2021
Tipo de documento:
Article